A series of novel matrix metalloproteinase inhibitors is described in which
selectivity between MMP and 'sheddase' activity has been achieved and whic
h demonstrate potent in vivo activity in models of arthritis and cancer. (C
) 2001 Elsevier Science Ltd. All rights reserved.